Neurotoxicity of stem cell mobilization chemotherapy with vinorelbine in myeloma patients after bortezomib treatment

Sandra Keller(University Hospital of Bern), Thomas Pabst(University Hospital of Bern), Beatrice U. Mueller, Kurt Leibundgut(Swiss Red Cross), Behrouz Mansouri Taleghani(University of Bern), Katja Seipel(University of Bern), Urban Novak(University of Bern)

Leukemia Research

April 17, 2015

10.1016/j.leukres.2015.03.015

Cited by 18

Related Papers

Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC)

|Journal of Clinical Oncology|2004|300

Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome

|Blood|2010|189

Intensified Therapy of Acute Lymphoblastic Leukemia in Adults: Report of the Randomized GRAALL-2005 Clinical Trial

|Journal of Clinical Oncology|2018|152

Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network

|The Lancet|2024|135

Patient blood management (PBM) in pregnancy and childbirth: literature review and expert opinion

|Archives of Gynecology and Obstetrics|2019|96